X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
ASTRAZENECA PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,285365-   
Low Rs634264-   
Sales per share (Unadj.) Rs189.6108.7-  
Earnings per share (Unadj.) Rs-0.2-27.4-  
Cash flow per share (Unadj.) Rs3.8-22.7-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.685.3-  
Shares outstanding (eoy) m25.00168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 174.9%   
Avg P/E ratio x-4,712.7-11.5 41,041.7%  
P/CF ratio (eoy) x249.6-13.9 -1,801.3%  
Price / Book Value ratio x14.03.7 379.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,98853,081 45.2%   
No. of employees `0001.64.3 36.3%   
Total wages/salary Rs m1,6053,331 48.2%   
Avg. sales/employee Rs Th3,040.24,273.4 71.1%   
Avg. wages/employee Rs Th1,029.2776.0 132.6%   
Avg. net profit/employee Rs Th-3.3-1,076.8 0.3%   
INCOME DATA
Net Sales Rs m4,74018,346 25.8%  
Other income Rs m92128 71.7%   
Total revenues Rs m4,83218,474 26.2%   
Gross profit Rs m-130-3,179 4.1%  
Depreciation Rs m101792 12.8%   
Interest Rs m0497 0.0%   
Profit before tax Rs m-139-4,339 3.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5271 1.9%   
Profit after tax Rs m-5-4,623 0.1%  
Gross profit margin %-2.7-17.3 15.8%  
Effective tax rate %-3.7-6.2 58.6%   
Net profit margin %-0.1-25.2 0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72613,437 20.3%   
Current liabilities Rs m2,4357,560 32.2%   
Net working cap to sales %6.132.0 19.2%  
Current ratio x1.11.8 63.0%  
Inventory Days Days74111 66.5%  
Debtors Days Days41124 32.9%  
Net fixed assets Rs m1,0357,832 13.2%   
Share capital Rs m5085 58.7%   
"Free" reserves Rs m9420-   
Net worth Rs m1,71614,399 11.9%   
Long term debt Rs m05,060 0.0%   
Total assets Rs m4,15627,201 15.3%  
Interest coverage xNM-7.7-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.7 169.1%   
Return on assets %-0.1-15.2 0.8%  
Return on equity %-0.3-32.1 0.9%  
Return on capital %0-19.8 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-81,566 -0.5%  
From Investments Rs m-146-481 30.3%  
From Financial Activity Rs m8624,592 18.8%  
Net Cashflow Rs m7095,678 12.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.04 Rs / ZAR

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: WOCKHARDT LTD.  SHASUN PHARMA  NATCO PHARMA  TORRENT PHARMA  ALEMBIC LTD  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 15, 2018 03:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS